Longevity Medicine
Moderate EvidenceAMPK activation and the TAME trial — diabetes drug as longevity intervention.
SGLT2 inhibitors extend lifespan in animal models and reduce all-cause mortality in humans. Here is what the evidence shows—and how they fit alongside rapamycin and metformin.
Metformin may impair mitochondrial adaptations to exercise in older adults. Learn who should cycle off, when to skip doses, and how to get the best of both.
Evidence-based guide to metformin dosing in CKD patients. eGFR cutoffs, lactic acidosis risk, FDA label changes, and how longevity physicians adjust protocol for renal impairment.
Head-to-head comparison of berberine and metformin for glucose control, lipids, and longevity. Both activate AMPK — but how do they really compare?
Complete guide to metformin side effects in non-diabetics using it for longevity. B12 depletion, GI issues, exercise blunting, muscle loss risk, and mitigation strategies.
Head-to-head comparison of metformin and berberine for longevity, AMPK activation, blood sugar, and exercise compatibility. Evidence, dosing, and which to choose.
A physician's honest comparison of rapamycin and metformin for longevity. mTOR inhibition vs AMPK activation, evidence quality, dosing, and who should use which.
Evidence-based metformin dosing for anti-aging in non-diabetics. The TAME trial, MILES study dosages, titration protocols, and what physicians actually prescribe off-label.
Can a diabetes drug slow aging? The TAME trial, mechanistic rationale, and honest assessment of metformin as a longevity intervention.
